Pivekimab is a high-affinity humanised monoclonal antibody targeting CD123 (IL-3RA), which can be used to synthesise the ADC molecule pivekimab sunirine, for the study of acute myeloid leukaemia and blast plasmacytoid dendritic cell neoplasm (BPDCN).
Purity:
95.00%
CAS Number:
[2234335-84-1]
Target:
ADC Antibody|||Interleukin|||Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted
